Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2018 Jan 20

PMID 29349097

Citations 50

Authors

Shelley A Nass

Maryellen A Mattingly

Denise A Woodcock

Brenda L Burnham

Jeffrey A Ardinger

Shayla E Osmond

Amy M Frederick

Abraham Scaria

Seng H Cheng

Catherine R ORiordan

Affiliations

Soon will be listed here.

Abstract

The generation of clinical good manufacturing practices (GMP)-grade adeno-associated virus (AAV) vectors requires purification strategies that support the generation of vectors of high purity, and that exhibit a good safety and efficacy profile. To date, most reported purification schemas are serotype dependent, requiring method development for each AAV gene therapy product. Here, we describe a platform purification process that is compatible with the purification of multiple AAV serotypes. The method generates vector preparations of high purity that are enriched for capsids with full vector genomes, and that minimizes the fractional content of empty capsids. The two-column purification method, a combination of affinity and ion exchange chromatographies, is compatible with a range of AAV serotypes generated by either the transient triple transfection method or the more scalable producer cell line platform. In summary, the adaptable purification method described can be used for the production of a variety of high-quality AAV vectors suitable for preclinical testing in animal models of diseases.

Citing Articles

Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy.

Zwi-Dantsis L, Mohamed S, Massaro G, Moeendarbary E Viruses. 2025; 17(2).

PMID: 40006994 PMC: 11861813. DOI: 10.3390/v17020239.

Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification.

Duzenli O, Aslanidi G Biomedicines. 2025; 13(2).

PMID: 40002774 PMC: 11852678. DOI: 10.3390/biomedicines13020361.

Improved Recombinant Adeno-Associated Viral Vector Production via Molecular Evolution of the Viral Rep Protein.

Steininger T, Ottl V, Franken L, Frank C, Ohland P, Lopez Ferreiro M Int J Mol Sci. 2025; 26(3).

PMID: 39941089 PMC: 11818820. DOI: 10.3390/ijms26031319.

Chromatographic Purification and Polishing of AAV Particles.

Sedorovitz M, Byrne L, Betegon M Methods Mol Biol. 2024; 2848:249-257.

PMID: 39240527 DOI: 10.1007/978-1-0716-4087-6_15.

Therapeutic Application and Structural Features of Adeno-Associated Virus Vector.

Matsuzaka Y, Yashiro R Curr Issues Mol Biol. 2024; 46(8):8464-8498.

PMID: 39194716 PMC: 11353222. DOI: 10.3390/cimb46080499.

References

Martin J, Frederick A, Luo Y, Jackson R, Joubert M, Sol B . Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods. 2013; 24(4):253-69. DOI: 10.1089/hgtb.2013.046. View

Simonelli F, Maguire A, Testa F, Pierce E, Mingozzi F, Bennicelli J . Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2009; 18(3):643-50. PMC: 2839440. DOI: 10.1038/mt.2009.277. View

Maguire A, High K, Auricchio A, Wright J, Pierce E, Testa F . Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009; 374(9701):1597-605. PMC: 4492302. DOI: 10.1016/S0140-6736(09)61836-5. View

Burnham B, Nass S, Kong E, Mattingly M, Woodcock D, Song A . Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors. Hum Gene Ther Methods. 2015; 26(6):228-42. DOI: 10.1089/hgtb.2015.048. View

Halder S, Van Vliet K, Smith J, Duong T, McKenna R, Wilson J . Structure of neurotropic adeno-associated virus AAVrh.8. J Struct Biol. 2015; 192(1):21-36. PMC: 4617535. DOI: 10.1016/j.jsb.2015.08.017. View

Wang Q, Lock M, Prongay A, Alvira M, Petkov B, Wilson J . Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin. Mol Ther Methods Clin Dev. 2015; 2:15040. PMC: 4632836. DOI: 10.1038/mtm.2015.40. View

Choudhury S, Fitzpatrick Z, Harris A, Maitland S, Ferreira J, Zhang Y . In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. Mol Ther. 2016; 24(7):1247-57. PMC: 5088762. DOI: 10.1038/mt.2016.84. View

Ayuso E, Mingozzi F, Bosch F . Production, purification and characterization of adeno-associated vectors. Curr Gene Ther. 2010; 10(6):423-36. DOI: 10.2174/156652310793797685. View

Khani S, Pawlyk B, Bulgakov O, Kasperek E, Young J, Adamian M . AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci. 2007; 48(9):3954-61. DOI: 10.1167/iovs.07-0257. View

10.

Nathwani A, Tuddenham E, Rangarajan S, Rosales C, McIntosh J, Linch D . Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011; 365(25):2357-65. PMC: 3265081. DOI: 10.1056/NEJMoa1108046. View

11.

Zhou J, Yang X, Wright J, High K, Couto L, Qu G . PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9. J Virol Methods. 2011; 173(1):99-107. DOI: 10.1016/j.jviromet.2011.01.013. View

12.

Xiao X, Li J, Samulski R . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998; 72(3):2224-32. PMC: 109519. DOI: 10.1128/JVI.72.3.2224-2232.1998. View

13.

Mietzsch M, Grasse S, Zurawski C, Weger S, Bennett A, Agbandje-Mckenna M . OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther. 2013; 25(3):212-22. PMC: 3955967. DOI: 10.1089/hum.2013.184. View

14.

Hauswirth W, Aleman T, Kaushal S, Cideciyan A, Schwartz S, Wang L . Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008; 19(10):979-90. PMC: 2940541. DOI: 10.1089/hum.2008.107. View

15.

Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J . Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods. 2007; 140(1-2):183-92. DOI: 10.1016/j.jviromet.2006.11.019. View

16.

ORiordan C, Lachapelle A, Vincent K, Wadsworth S . Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med. 2001; 2(6):444-54. DOI: 10.1002/1521-2254(200011/12)2:6<444::AID-JGM132>3.0.CO;2-1. View

17.

DiPrimio N, Asokan A, Govindasamy L, Agbandje-Mckenna M, Samulski R . Surface loop dynamics in adeno-associated virus capsid assembly. J Virol. 2008; 82(11):5178-89. PMC: 2395211. DOI: 10.1128/JVI.02721-07. View

18.

Thorne B, Takeya R, Peluso R . Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum Gene Ther. 2009; 20(7):707-14. DOI: 10.1089/hum.2009.070. View

19.

Yla-Herttuala S . Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012; 20(10):1831-2. PMC: 3464639. DOI: 10.1038/mt.2012.194. View

20.

Davidoff A, Ng C, Sleep S, Gray J, Azam S, Zhao Y . Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods. 2004; 121(2):209-15. DOI: 10.1016/j.jviromet.2004.07.001. View